Wells Fargo analyst Eva Fortea Verdejo downgraded Merus (MRUS) to Equal Weight from Overweight with a price target of $97, up from $95, after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97 per share in an all-cash transaction, representing a transaction value of $8B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus downgraded to Hold from Buy at Needham
- Merus up 38% at $94.82 after Genmab acquisition announcement at $97 per share
- Merus’s Strong Clinical Achievements and Potential Genmab Acquisition Drive Buy Rating
- Merus downgraded to Neutral from Buy at Citi
- Genmab acquires Merus for $97 per share in cash or $8B